Literature DB >> 30081240

Conformational heterogeneity of tau: Implication on intrinsic disorder, acid stability and fibrillation in Alzheimer's disease.

Benita Jebarupa1, Monita Muralidharan1, Arumugaperumal Arun1, Amit Kumar Mandal1, Gopa Mitra2.   

Abstract

The self-assembly of intrinsically disordered protein tau into paired helical filament forms one of the hallmarks of Alzheimer's disease. However, the facets of innately disordered structure of tau and its conversion to a β-sheet-rich fibril during several tauopathies are poorly understood. Here, we provide a direct insight into the ensemble of highly heterogeneous conformational families of tau at physiological pH, by nano-electrospray mass spectrometry coupled with ion mobility. The average collision cross section of the most unfolded conformer was higher by >2 fold than that of the most folded one. Acidic pH largely induced unfolding in tau, obliterating the compact conformers completely. The highly unfolded conformers were the key species bestowing the unusual solubility to tau at low pH, with limited contribution from intramolecular long-range interfaces giving rise to ordered conformers. Contrarily, alkaline pH shifted tau towards folded conformations due to charge neutralization, keeping the overall random coil architecture intact. Intriguingly, the heparin-induced in vitro aggregation propensity of the protein attenuated at both acidic and alkaline pH, illustrating the significance of altered conformations in pathological functions of tau. Our observations at low pH indicate that a reorganization of the intricate network of momentary long-range contacts in tau might have implication in its aggregation pathology. Disease-modifying therapies for Alzheimer's disease targeting either to disrupt the essential fibril-forming interaction at third microtubule-binding repeat of tau or to perturb specific binding interaction of tau with endogenous polyanionic species might be of high benefit.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Intrinsically disordered protein; Ion mobility mass spectrometry; Paired helical filament; Tau

Mesh:

Substances:

Year:  2018        PMID: 30081240     DOI: 10.1016/j.bpc.2018.07.005

Source DB:  PubMed          Journal:  Biophys Chem        ISSN: 0301-4622            Impact factor:   2.352


  7 in total

1.  Three-repeat and four-repeat tau isoforms form different oligomers.

Authors:  Hedieh Shahpasand-Kroner; Jennifer Portillo; Carter Lantz; Paul M Seidler; Natalie Sarafian; Joseph A Loo; Gal Bitan
Journal:  Protein Sci       Date:  2022-01-07       Impact factor: 6.993

Review 2.  Pharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimer's disease.

Authors:  Jangampalli Adi Pradeepkiran; Arubala P Reddy; P Hemachandra Reddy
Journal:  Drug Discov Today       Date:  2018-11-16       Impact factor: 7.851

Review 3.  High-Speed Atomic Force Microscopy Reveals the Structural Dynamics of the Amyloid-β and Amylin Aggregation Pathways.

Authors:  Takahiro Watanabe-Nakayama; Bikash R Sahoo; Ayyalusamy Ramamoorthy; Kenjiro Ono
Journal:  Int J Mol Sci       Date:  2020-06-16       Impact factor: 5.923

4.  Differential binding affinity of tau repeat region R2 with neuronal-specific β-tubulin isotypes.

Authors:  Vishwambhar Vishnu Bhandare; Bajarang Vasant Kumbhar; Ambarish Kunwar
Journal:  Sci Rep       Date:  2019-07-25       Impact factor: 4.379

5.  The nickel-chelator dimethylglyoxime inhibits human amyloid beta peptide in vitro aggregation.

Authors:  Stéphane L Benoit; Robert J Maier
Journal:  Sci Rep       Date:  2021-03-23       Impact factor: 4.379

Review 6.  Tau Seeding Mouse Models with Patient Brain-Derived Aggregates.

Authors:  Aiko Robert; Michael Schöll; Thomas Vogels
Journal:  Int J Mol Sci       Date:  2021-06-07       Impact factor: 5.923

Review 7.  Mechanistic roles for altered O-GlcNAcylation in neurodegenerative disorders.

Authors:  Aaron T Balana; Matthew R Pratt
Journal:  Biochem J       Date:  2021-07-30       Impact factor: 3.766

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.